AzTrials
AzTrials

Type 1 DiabetesATT1DNCT07676565

Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

An observational study of Type 1 Diabetes, run by Indiana University at 17 sites in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Type 1 Diabetes
How many people
300 participants
Where
17 sitesUnited States
Study dates
24 Mar 2026to Apr 2028
How long will I take part?
1 Year
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults with type 1 diabetes who have been prescribed an adjunctive medications (GLP-1RA or SGLTi) as a part of their clinical care by their health care providers.

Who may be able to join

  • Adults ≥18 years of age
  • Clinical diagnosis of T1D
  • GLP-1RA or SGLTi (SGLT-1 and SGLT-2 inhibitors) drug prescribed by their provider for any indication as part of usual care with use for no more than 1 week
  • Use of CGM and availability of CGM data for 1 month prior to enrollment and expected to be available throughout the study
  • Willing and able to provide informed consent

Who cannot join

  • No exclusion criteria other than those not meeting inclusion criteria above

Trial locations and contacts

17 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Kanchan Bhasin, MBBS, MS contact

(317)-278-2752

kanbhas@iu.edu

17 sites in 1 country

United States17 sites, 17 recruiting

  • Emory University

    Atlanta, Georgia, 30303

    sabeena usman, 404-251-8959, sabeena.usman@emory.edu

    Francisco Pasquel, MD

    Recruiting

  • Harvard Medical School

    Boston, Massachusetts, 02115

    Grace Ordonez, 617-732-4245, gordonez@bwh.harvard.edu

    Zeb Saeed, MD

    Recruiting

  • Northwestern University

    Chicago, Illinois, 60611

    Evelyn Fronczyk, 312-908-9002, evelyn.guevara@northwestern.edu

    Grazia Aleppo, MD

    Recruiting

  • University of Cincinnati

    Cincinnati, Ohio, 45267

    Alyssa Randolph, 513-558-3427, randolas@ucmail.uc.edu

    Andrew Welch, DO

    Recruiting

  • Ohio State University

    Columbus, Ohio, 43203

    Aleitha Gates, 614-814-0771, aleitha.gates@osumc.edu

    Kathleen Dungan, MD

    Recruiting

  • Henry Ford Hospital

    Detroit, Michigan, 48202

    Lydia Oehring, 313-916-3906, loehrin1@hfhs.org

    Davida Kruger, ANP

    Recruiting

  • University of Louisville

    Louisville, Kentucky, 40202

    Tiffanie Shelburne, 502-852-1411, tiffanie.shelburne@louisville.edu

    Sathya S. Krishnasamy, M.D.

    Recruiting

  • University of Miami

    Miami, Florida, 33136

    Julia Martins de Oliveira, 305-243-3466, Jmd636@miami.edu

    Francesco Vendrame, MD, PhD

    Recruiting

  • HealthPartners, International Diabetes Center

    Minneapolis, Minnesota, 55416

    Caitlin M. Moening, 952-993-9605, caitlin.m.moening@healthpartners.com

    Anders L. Carlson, MD

    Recruiting

  • NYU Grossman School of Medicine

    New York, New York, 10016

    Zoe Rimler, 212-263-2544, Zoe.Rimler@nyulangone.org

    Mollie O'Connor, MD

    Recruiting

  • Mount Sinai

    New York, New York, 10029

    Sophie Baun, 212-241-4301, sophie.baum@mssm.edu

    Carol Levy, MD

    Recruiting

  • Hoag Memorial Hospital

    Newport Beach, California, 92663

    Brittany Dennis, 949-764-6896, Brittany.Dennis@hoag.org

    David Ahn, MD

    Recruiting

  • Eastern Virginia Medical Center, Old Dominion University

    Norfolk, Virginia, 23510

    Shayreen Gomez Ocasio, 757-446-8485, socasiog@odu.edu

    Manasi S. Shah, MD

    Recruiting

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

    Reagan TeKolste, 402-552-9662, rtekolste@unmc.edu

    Shubham Agarwal, MD

    Recruiting

  • Maine Health Research Institute

    Portland, Maine, 04102

    Debra Burris, 207-662-2467, debra.burris@mainehealth.org

    Jay Ambalavanan, MD

    Recruiting

  • University of Rochester

    Rochester, New York, 14642

    Samantha DelMartino, 585-273-3877, Samantha_delmartino@urmc.rochester.edu

    Sara R. MacLeod, DO, MPH

    Recruiting

  • University of California, San Francisco (UCSF)

    San Francisco, California, 94158

    Nicole Sears, 628-278-8760, nicole.sears@ucsf.edu

    Laya Ekhlaspour, MD

    Recruiting

Other trials in United States

About this study

Official title: Safety and Efficacy of Adjunct Therapies in Adults With Type 1diabetes: Multicenter, Registry Study

This will be a multicenter registry-based study to evaluate safety and efficacy of GLP-1RA and SGLTi therapies in adjunct to insulin in adults with type 1 diabetes (T1D) over 1 year. This study will enroll participants who have been prescribed adjunct therapy as part of usual care.

Conditions
Type 1 Diabetes
Keywords
Type 1 Diabetes, GLP1-RA, SGLT2i
Medical subject headings
Diabetes Mellitus, Type 1

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in HbA1c by type of therapy

    Change in HbA1c from baseline to over 1 year by those receiving GLP-1RA and SGLTi

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Jun 2026
  2. Study start24 Mar 2026
  3. Primary completionApr 2028 (estimated)
  4. Study completionApr 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
300 participants (estimated)
Target duration
1 Year
IDs, dates and publications
ClinicalTrials.gov ID
NCT07676565
Sponsor's protocol ID
28772
Other IDs
ATT1D
Acronym
ATT1D
Status last verified
Oct 2026
First submitted
24 Jun 2026
Last updated
16 Oct 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Type 1 Diabetes, run by Indiana University at 17 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 17 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Kanchan Bhasin, MBBS, MS ((317)-278-2752, kanbhas@iu.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in HbA1c by type of therapy (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07676565.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in